Aquestive Therapeutics Inc AQST

NAS: AQST | ISIN: US03843E1047   30/04/2025
2,925 USD (+3,17%)
(+3,17%)   30/04/2025

7 april 2021 · AQST INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Against Aquestive Therapeutics, Inc. · Persbericht

18 maart 2021 · AQST INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Against Aquestive Therapeutics, Inc. · Persbericht

18 maart 2021 · ROSEN, NATIONAL TRIAL COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - AQST · Persbericht

16 maart 2021 · Moore Kuehn, PLLC Encourages Investors of AQST, REGI or APA to Contact Law Firm · Persbericht

16 maart 2021 · Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aquestive Therapeutics, Inc. (AQST) · Persbericht

9 maart 2021 · Aquestive Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update · Persbericht

5 maart 2021 · SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm · Persbericht

5 maart 2021 · Aquestive Therapeutics to Host Investor & Analyst Virtual Epinephrine Drug Delivery R&D Event on March 25 at 9:00 a.m. ET · Persbericht

4 maart 2021 · ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - AQST · Persbericht

3 maart 2021 · AQST INVESTOR LAWSUIT DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Against Aquestive Therapeutics, Inc. · Persbericht

3 maart 2021 · AQST Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Aquestive Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm · Persbericht

2 maart 2021 · Pomerantz Law Firm Announces the Filing of a Class Action against Aquestive Therapeutics, Inc. and Certain Officers - AQST · Persbericht

25 februari 2021 · Aquestive Therapeutics Reaffirms Near-Term NDA Resubmission for Libervant™ (diazepam) Buccal Film Following FDA Feedback · Persbericht

17 februari 2021 · Aquestive Therapeutics to Announce Fourth Quarter and Year End 2020 Financial Results and Recent Business Highlights on March 9 and Host Conference Call on March 10 at 8:00 a.m. ET · Persbericht

9 februari 2021 · Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors · Persbericht

28 januari 2021 · Aquestive Therapeutics Appoints Mark Lepore, MD, as Chief Medical Officer for Allergy · Persbericht

21 januari 2021 · Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole Oral Film for ALS Treatment · Persbericht

7 januari 2021 · Aquestive Therapeutics Provides Business Update · Persbericht

4 januari 2021 · Aquestive Therapeutics to Present at Two Upcoming Investor Conferences · Persbericht

Mijn selecties